Detection of hepatitis b virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment

Current HIV Research

Volumn 9, Issue 4, 2011, Pages 263-269

  Aghasadeghi, Mohammad Reza ^a   Bahramali, Golnaz ^a   Sadat, Seyed Mehdi ^a   Far, Ahmad Farahani ^a,b   Mohraz, Minoo ^c   Siadat, Seyed Davar ^a   Mostafavi, Ehsan ^a   Memarnejadian, Arash ^a   Ardestani, Mehdi Shafiee ^a   Vahabpour, Rouhollah ^a   Saraji, Alireza Azizi ^a,d   Delbaz, Seyed Ali ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

HBV; HIV; Iran; Lamivudine; Mono coinfection; Mutation

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; LAMIVUDINE; VIRUS DNA; ZIDOVUDINE;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; IRAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MOLECULAR PHYLOGENY; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; POLYMERASE CHAIN REACTION; PROTEIN MOTIF; TREATMENT DURATION; UNSAFE SEX; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS STRAIN;

EID: 79960026083     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211796320315     Document Type: Article

References (29)

1. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
2. Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577.
3. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
4. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus- HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 2006; 43: 904-910.
5. Benhamou Y. Update on the treatment of hepatitis B virus infection in patients infected by the human immunodeficiency virus. Med Mal Infec 2004; 34: 27-29.
6. UNAIDS. AIDS epidemic update: Special report on HIV/AIDS: 2006. Available at: http://www.unaids.org/pub/EpiReport/2006.2006_EpiUpdate.en.pdf. Accessed March 23, 2008
7. Thio CL, Locarnini S. Treatment of HBV/HIV coinfection: clinical and virologic issues. AIDS Rev 2007; 9: 40-53.
8. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163: 1138-1140.
9. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11: 597-606.
10. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-1310.
11. Ramos B, Nunez M, MartinCarbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44: 557-561.
12. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306.
13. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
14. Mutimer D, Dusheiko G, Barrett, C, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 809-815.
15. Delaney WE, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003; 77(21): 11833-11841.
16. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the fingers subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virolog 2002; 299: 88-99.
17. Leung N, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after three years of therapy. Hepatology 2001; 33: 1527-15232.
18. Bahramali G, Sadeghizadeh M, Amini-Bavil-Olyaee S, et al. Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients. World J Gastroenterol 2008; 14: 5448-5453.
19. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16: 111-120.
20. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4: 406-425.
21. Felsenstein J. Confidence limits on phylogenesis: An approach using the bootstrap. Evolution 1985; 39: 783-791.
22. Tamura K, Dudley J, Nei M, et al. MEG A4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol.2007; 24: 1596-1599.
23. Svicher V, Gori C, Trignetti M, et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 2009; 50: 461-470.
24. Iacomi F, Vincenti D, Vairo F, et al. Effect of HIV coinfection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2009; 81:1151-1156.
25. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-870.
26. Carman, WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral HepaT 1997; 4 Suppl 1: 11-20.
27. Sheldon J, SorianoV. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61: 766-768.
28. Chen WN, Oon CJ. Hepatitis B virus surface antigen (HBsAg) mutants in Singapore adults and vaccinated children with high antihepatitis B virus antibody levels but negative for HBsAg. JClin Microbiol 2000; 38: 2793-4.
29. Buti M, Cotrina M, Valdes A, et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002; 36: 445-446.